Our study showed that knockdown of eIF3a reduced the CDK4 and CDK6 expression in DLBCL cells, suggesting that targeting eIF3a has a potential anti-tumor effect in DLBCL. The gene discussed is CDK6; the disease is diffuse large B-cell lymphoma.